AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 290: H2417-H2423, 2006. First published January 13, 2006; doi:10.1152/ajpheart.01170.2005
0363-6135/06 $8.00
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/6/H2417    most recent
01170.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (18)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grobe, J. L.
Right arrow Articles by Katovich, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grobe, J. L.
Right arrow Articles by Katovich, M. J.

Chronic angiotensin-(1–7) prevents cardiac fibrosis in DOCA-salt model of hypertension

Justin L. Grobe, Adam P. Mecca, Haoyu Mao, and Michael J. Katovich

Department of Pharmacodynamics, College of Pharmacy, University of Florida, Gainesville, Florida

Submitted 4 November 2005 ; accepted in final form 3 January 2006


   ABSTRACT
TOP
 ABSTRACT
MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Cardiac remodeling is a hallmark hypertension-induced pathophysiology. In the current study, the role of the angiotensin-(1–7) fragment in modulating cardiac remodeling was examined. Sprague-Dawley rats underwent uninephrectomy surgery and were implanted with a deoxycorticosterone acetate (DOCA) pellet. DOCA animals had their drinking water replaced with 0.9% saline solution. A subgroup of DOCA-salt animals was implanted with osmotic minipumps, which delivered angiotensin-(1–7) chronically (100 ng·kg–1·min–1). Control animals underwent sham surgery and were maintained on normal drinking water. Blood pressure was measured weekly with the use of the tail-cuff method, and after 4 wk of treatment, blood pressure responses to graded doses of angiotensin II were determined by direct carotid artery cannulation. Ventricle size was measured, and cross sections of the heart ventricles were paraffin embedded and stained using Masson's Trichrome to measure interstitial and perivascular collagen deposition and myocyte diameter. DOCA-salt treatment caused significant increases in blood pressure, cardiac hypertrophy, and myocardial and perivascular fibrosis. Angiotensin-(1–7) infusion prevented the collagen deposition effects without any effect on blood pressure or cardiac hypertrophy. These results indicate that angiotensin-(1–7) selectively prevents cardiac fibrosis independent of blood pressure or cardiac hypertrophy in the DOCA-salt model of hypertension.

deoxycorticosterone acetate; blood pressure; cardiac remodeling

CARDIAC FIBROSIS is a major facet of hypertensive cardiac disease, and it interferes with the normal function and structure of the myocardium (8, 61, 62). Increased deposition of basement membrane collagen is a hallmark of the remodeling process, and it results in an increase in cardiac tissue stiffness. This remodeling predisposes the patient to an increased risk of adverse cardiac events, including myocardial ischemia, infarction, arrhythmias, and sudden cardiac death (61). Thus prevention and reversal of cardiac fibrosis are essential in the management of hypertensive heart disease.

The renin-angiotensin-aldosterone system (RAAS) has been suggested to participate in the development of end-organ damage in hypertensive patients (2, 11). Support for this concept comes from clinical trials demonstrating that treatment of hypertensive patients with either angiotensin-converting enzyme (ACE) inhibitors (38, 53) or ANG II type 1 (AT1) receptor blockers (41, 60) provides significant protection from, and even reversal of, end-organ damage. Animal studies have also demonstrated that ACE inhibitors and AT1 receptor antagonists prevent cardiovascular injury (23, 55, 56) as well as protect against renal (3, 55, 57) and cerebral (55–57) injury.

The use of these antagonists of the RAAS not only reduces the formation and actions of ANG II but also results in a significant elevation of another fragment of the RAAS, angiotensin-(1–7) [ANG-(1–7)] (17, 25). This peptide, which can be generated locally in the myocardium (47), has been reported to work antagonistically to ANG II and has been implicated in protecting against cardiac pathophysiology (49). Recently, Loot et al. (31) demonstrated that chronic infusion of ANG-(1–7) improved endothelial function and coronary perfusion and preserved cardiac function in an animal model of heart failure. ANG-(1–7) has also been shown to significantly increase cardiac output and stroke volume in rodents (18) and to improve contractile function in isolated perfused rat hearts (46). Using a fusion protein to generate a transgenic rat model that overproduces ANG-(1–7), Santos et al. (49) showed that ANG-(1–7) reduced the induction of cardiac hypertrophy and the duration of reperfusion arrhythmias and improved postischemic function in isolated perfused hearts. Thus ANG-(1–7) may be an important component of the RAAS that has opposing actions to ANG II, and it may provide protective action(s) in the heart and possibly other end organs. ANG-(1–7) also recently has been reported to inhibit the growth of cardiac myocytes in vitro (59), suggesting that elevated levels of ANG-(1–7) may also protect against cardiac hypertrophy in hypertension. Interestingly, blockade of ANG-(1–7) receptors has also been shown to reverse the antihypertensive effects of long-term administration of ACE inhibitors (22). Thus ANG-(1–7) may play a significant role in the beneficial effects on the cardiovascular system attributed to some antihypertensive agents.

Not only has ANG II been implicated in the development of cardiac fibrosis, but so has the aldosterone component of the RAAS (19). It has been demonstrated in experimental studies utilizing uninephrectomized rats that deoxycorticosterone acetate supplementation (DOCA-salt) treatment results in significant cardiac and renal remodeling, including interstitial fibrosis and hypertrophy (15, 69). The purpose of this study was to determine whether chronically elevated levels of ANG-(1–7) alter the development of hypertension, cardiac hypertrophy, and/or cardiac fibrosis in the DOCA-salt model of hypertension.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 MATERIALS AND METHODS
RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 
Animals. Male Sprague-Dawley rats weighing between 170 and 250 g were used for this study. Animals were housed in a temperature- and humidity-controlled room in standard shoebox cages and maintained on a 12:12-h light-dark schedule with free access to food and water. All procedures were approved by the University of Florida Institutional Animal Care and Use Committee.

Chemicals. ANG-(1–7) was obtained from Bachem Bioscience. DOCA was purchased from Sigma Aldrich (St. Louis, MO).

DOCA-salt model. Animals were anesthetized with an intramuscular injection of a ketamine, xylazine, and acepromazine mixture (30, 6, and 1 mg/kg im, respectively) before uninephrectomy. During the surgery, 15 animals were implanted with a subcutaneous pellet of DOCA (40 mg). Seven of these animals were additionally implanted with a subcutaneous osmotic pump that delivered ANG-(1–7) (100 ng·kg–1·min–1) for the duration of the experiment. After surgery (and for the remainder of the experiment), drinking water for these animals was replaced with 0.9% saline solution. Ten animals underwent a sham surgery and were maintained on normal drinking water. Four additional sham animals were implanted with only an ANG-(1–7) pump.

Indirect blood pressure. Systolic blood pressures were determined weekly by an indirect method utilizing a tail-cuff and pneumatic pulse sensor as previously reported (24). Briefly, animals were heated with the use of a 200-W heat lamp for 3–5 min before being restrained in a heated Plexiglas restrainer to which the animals had been conditioned before the experiment. A pneumatic pulse sensor was then attached to the tail distal to a pressure cuff under the control of a Programmed Electro-Sphygmomanometer (Narco). Voltage outputs from the pressure sensor bulb and inflation cuff were recorded and analyzed electronically using a PowerLab signal transduction unit and associated Chart software (ADInstruments). At least three separate indirect pressures were averaged for each animal.

Direct blood pressure/acute ANG II responses. After 4 wk of chronic treatment, animals underwent carotid artery and jugular cannula implantation surgery as previously reported (32). Briefly, animals were anesthetized with a mixture of ketamine, xylazine, and acepromazine (30, 6, and 1 mg/kg im, respectively). A polyethylene cannula (PE-50, Clay Adams) was introduced into the carotid artery for direct blood pressure measurements, whereas a silicone elastomer cannula (Helix Medical) was introduced into the descending jugular vein for acute intravenous injections of drug. Both cannulas were filled with heparin saline (40 U/ml; Sigma) and sealed with stylets. Animals were allowed 24 h to recover before experiments were performed. Direct blood pressure responses to acute intravenous injections of ANG II (5–320 ng/kg) in awake, freely moving animals were recorded by connecting the carotid cannula to a liquid pressure transducer, which was interfaced to a PowerLab (ADInstruments) signal transduction unit. Data were analyzed by using the Chart program that was supplied with the PowerLab system.

Cardiac remodeling. Cardiac remodeling was determined at the end of the direct blood pressure experiment by ventricular hypertrophy and cardiac fibrosis after 4 wk of respective treatments. After the acute ANG II blood pressure experiment, animals were anesthetized by inhaled halothane and then euthanized by decapitation. Ventricular hypertrophy was determined by measuring ventricle mass normalized by body mass. Cross sections of the ventricles were then embedded in paraffin, sectioned at 4 µm, and stained for collagen deposition using Masson's Trichrome. Single sections from each animal were then viewed and photographed with a Moticam 1000 digital camera (Motic; Richmond, BC, Canada) under x10 (whole heart) and x250 (perivascular collagen and myocyte diameter) magnifications. The collagen content of the left ventricle wall was determined by measuring the blue stain density of the left wall (from the septum in the posterior to the septum in the anterior) and was normalized to the red stain density of the same portion of the image. The area of blue-stained collagen surrounding the left anterior descending coronary artery was measured and normalized to the area of the lumen of the vessel. Myocyte cross-sectional diameter was also measured to confirm ventricular hypertrophy results. Color density, perivascular collagen and lumen areas, and myocyte diameter were determined using the ImageJ program from National Institutes of Health (42).

Statistics. Basal direct blood pressure and ventricular hypertrophy (by mass and by myocyte diameter) were analyzed by two-way ANOVA, whereas indirect blood pressures and direct blood pressure responses to graded, acute doses of ANG II were analyzed by two-way ANOVA with repeated measures. Cardiac fibrosis measurements were compared by using the more stringent nonparametric Kruskal-Wallis ANOVA, followed by post hoc Mann-Whitney U tests. Data were considered significantly different with P < 0.05.


   RESULTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
DISCUSSION
 GRANTS
 REFERENCES
 
Indirect blood pressure. DOCA-salt treatment caused a significant increase (P = 0.006) in systolic blood pressure over the course of the experiment. ANG-(1–7), when infused simultaneously, failed to prevent these increases (P = 0.22) (Fig. 1). ANG-(1–7), when infused alone, did not significantly alter blood pressure when compared with sham-implanted animals (P = 0.69; data not shown).


Figure 1
View larger version (20K):
[in this window]
[in a new window]
  		Fig. 1. Indirect blood pressure (BP). DOCA-salt treatment led to a significant increase in systolic blood pressure as measured by indirect tail-cuff method (P = 0.006). Chronic infusion of ANG-(1–7) had no effect on systolic blood pressure increases due to DOCA-salt treatment (P = 0.22). Data are presented as means ± SE.

 
Direct blood pressure/acute ANG II responses. Direct pressure measurements confirmed that whereas DOCA-salt treatment significantly increased pressure (P = 0.007), ANG-(1–7) had no effect (P = 0.20) on basal systolic blood pressure [sham, 129.2 ± 3.7 (mean ± SE); DOCA, 160.0 ± 5.2; DOCA + ANG-(1–7), 171.6 ± 10.8; ANG-(1–7) alone, 143.8 ± 21.0]. In addition, DOCA-salt treatment significantly potentiated (P = 0.02), and ANG-(1–7) infusion had no effect (P = 0.41) on, the dose-response curves to acute, graded injections of ANG II (Fig. 2).


Figure 2
View larger version (20K):
[in this window]
[in a new window]
  		Fig. 2. Mean arterial pressure (MAP) responses to acute ANG II injection. DOCA-salt treatment significantly potentiated dose-response curve to acute ANG II (P = 0.02). Chronic ANG-(1–7) had no effect (P = 0.41) on acute responses to ANG II. Data are presented as means ± SE.

 
Cardiac remodeling. DOCA-salt treatment significantly increased ventricle mass (P = 0.02), and ANG-(1–7) failed to prevent this effect (P = 0.35) (Fig. 3A). These effects were confirmed by measurement of myocyte diameter, which uncovered a significant increase in size with DOCA-salt treatment (P < 0.0001) but no effect of ANG-(1–7) (P = 0.71) (Fig. 3B).


Figure 3
View larger version (19K):
[in this window]
[in a new window]
  		Fig. 3. Ventricular hypertrophy. A: DOCA-salt treatment significantly increased heart mass (P = 0.02). Chronic ANG-(1–7) had no effect on hypertrophy due to DOCA-salt treatment (P = 0.35). B: cardiac myocyte diameter was also significantly increased by DOCA-salt treatment (P < 0.0001), but chronic ANG-(1–7) had no effect (P = 0.71). Data are presented as means ± SE. *P < 0.05 vs. sham.

 
A significant increase in left ventricular wall fibrosis was observed with DOCA-salt treatment (P = 0.04 vs. sham), and chronic ANG-(1–7) treatment significantly prevented this trend (P = 0.04 vs. DOCA) (Fig. 4). Whereas the increase in ventricular wall fibrosis is only ~4%, this value is most likely diluted by our measurement of collagen in the entire left ventricular wall at x10 magnification (as opposed to the common method of measuring selected "representative samples" at high magnification). Clearly, from Fig. 4B, analysis of "representative areas" within the left wall would lead to much larger relative changes.


Figure 4
View larger version (38K):
[in this window]
[in a new window]
  		Fig. 4. Left ventricle wall fibrosis. A: DOCA-salt treatment caused a significant increase in collagen deposition in left ventricle wall. Chronic ANG-(1–7) significantly prevented this increase. Data are presented as means ± SE. *P < 0.05 vs. sham; {dagger}P < 0.05 vs. DOCA. B: representative images of mid-myocardium at x250 magnification, stained with Masson's Trichrome. Blue color indicates collagen fibers.

 
DOCA-salt treatment further resulted in a significant (P = 0.0002 vs. sham) increase in perivascular collagen deposition around the left anterior descending coronary artery, and ANG-(1–7) completely prevented this effect (P = 0.0007 vs. DOCA) (Fig. 5).


Figure 5
View larger version (33K):
[in this window]
[in a new window]
  		Fig. 5. Perivascular fibrosis. A: DOCA-salt significantly increased perivascular collagen around left anterior descending coronary artery. Chronic ANG-(1–7) significantly prevented this effect. Data are presented as means ± SE. *P < 0.05 vs. sham; {dagger}P < 0.05 vs. DOCA. B: representative images of perivascular collagen surrounding left anterior descending coronary artery stained with Masson's Trichrome. Blue color indicates collagen fibers.

 

   DISCUSSION
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
GRANTS
 REFERENCES
 
In this study, DOCA-salt treatment resulted in increases in blood pressure, acute pressor responses to ANG II, cardiac hypertrophy, and mid-myocardial and perivascular fibrosis. The ANG-(1–7) fragment had no effect on the elevated blood pressure, acute pressor responses, or cardiac hypertrophy but significantly prevented the cardiac mid-myocardial and perivascular fibrosis in the DOCA-salt hypertensive rat model.

DOCA treatment in uninephrectomized rats drinking 1.0% NaCl has previously been shown to cause hypertension, cardiac hypertrophy, and interstitial and perivascular fibrosis (15, 69). These cardiac effects are mediated via mineralocorticoid receptors (44, 64, 66) and are not observed in animals on a low-salt diet (9). Others (26, 37) have suggested the involvement of AT1 receptors in the fibrosis associated with DOCA-salt treatment. Elevation of cardiac AT1 receptors associated with DOCA-salt treatment may potentiate the well-described fibrotic effect of ANG II. There is evidence that the trigger for cardiac fibrosis in this animal model is coronary vasculitus, because the inflammatory cell infiltration occurs within a few days of DOCA treatment (67).

In a study by Young et al. (69), the cardiac hypertrophy response to DOCA treatment was restricted to the left ventricle, whereas the collagen deposition was indistinguishable between left and right ventricle, thus supporting a humoral, rather than a hemodynamic, etiology. Further support for a humoral etiology for collagen deposition comes from Weber's (63) laboratory, where spironolactone prevented aldosterone-induced cardiac fibrosis without lowering blood pressure. Additionally, interstitial and perivascular fibrosis can be produced by mineralocorticoid and salt without substantial hypertension or cardiac hypertrophy (69). Young et al. (69) also demonstrated that central infusion of a mineralocorticoid receptor antagonist lowered blood pressure but did not alter the pattern of cardiac fibrosis, further suggesting an independence of fibrosis and blood pressure. Our results also demonstrate that the fibrosis observed in this model was found in both the right and left ventricle walls (right ventricle data not shown), and such fibrosis appears to be independent of both blood pressure and hypertrophy.

The effects of DOCA on cardiac hypertrophy have been postulated to involve ANG II or transforming growth factor-beta (TGF-beta) (58, 68). Whether these same mechanisms are responsible for the cardiac fibrosis are not clear. Young and Funder (67) demonstrated that animals treated for as few as 8 days with DOCA-salt treatment demonstrated a significant increase in cardiac perivascular collagen deposition, with no changes in heart weight, and that the collagen formation was inhibited by a mineralocorticoid receptor antagonist (67). Further evidence that the cardiac hypertrophy and fibrosis may be independent includes results from Lekgabe et al. (27), who demonstrated that cardiac hypertrophy and the related markers of hypertrophy that were elevated in spontaneously hypertensive rats (SHR) compared with Wistar-Kyoto (WKY) rats were not reversed with chronic relaxin treatment, whereas the fibrosis and collagen content in the hearts of the SHR were normalized by relaxin treatment to levels observed in the WKY. In the current study, ANG-(1–7) also showed differential effects on hypertrophy and fibrosis in the DOCA-salt model of hypertension, suggesting different mechanisms may exist for these two end points of cardiac remodeling.

Nehme et al. (35) reported that both aldosterone and ANG II receptor antagonists significantly reduced the cardiac fibrosis induced by coronary artery ligation in male Wistar rats. The effects of the aldosterone receptor antagonist (spironolactone) were independent of changes in mean blood pressure. This form of experimental myocardial infarction in rats has been shown to activate the RAAS (39, 51). Spironolactone also has been shown to reduce arterial collagen production, independent of changes in systemic blood pressure in the SHR (6) and in an NG-nitro-L-arginine methyl ester plus ANG II with salt model of hypertension (45). As in the current study, Nehme et al. (35) also reported that these treatments did not prevent the cardiac hypertrophy induced in this myocardial infarction model. This is further evidence that the mechanisms for cardiac hypertrophy and fibrosis may be independent.

Generally, the actions of ANG-(1–7) are opposite of those attributed to ANG II (48). ANG-(1–7) has been reported to have intrinsic vasoactive effects in some studies (10, 22, 43, 50), whereas these effects are absent in other studies (14, 54, 65, 70). Bayorh et al. (5) demonstrated that the hypotensive effects of ANG-(1–7) were not observed in Dahl animals on a low-salt diet, and Eatman et al. (16) noted a gender difference in the vasodilatory action of ANG-(1–7) in Dahl rats. Neves et al. (36) recently reported that the vasodilatory effects of ANG-(1–7) are modulated during the estrous cycle. Thus the contrasting findings of ANG-(1–7) on the vasculature may be related to the differences in animal models studied, dose of ANG-(1–7), vascular bed studied, or the experimental condition (in vitro vs. in vivo) in which the peptide is evaluated. In the current study, at the dose of ANG-(1–7) infused, there was no effect on the basal blood pressure of normotensive Sprague-Dawley animals or those animals made hypertensive with DOCA-salt treatment. There are situations, such as in models of endothelial dysfunction (28), where the vasodilatory effects of ANG-(1–7) have been shown to be blunted. This may be the reason for a lack of effect in our hypertensive model. In the current study, no reduction in the pressor response to acute administration of ANG II was observed. Benter et al. (7) reported that infusion of ANG-(1–7) did not alter the pressor responses to ANG II or phenylephrine in WKY animals; however, it did reduce the response to these agents in the SHR. A higher dose of ANG-(1–7) was utilized in the Benter study compared with ours. Although there was no observable effect on blood pressure at the dose of ANG-(1–7) used in the current study, there was a significant attenuation of cardiac fibrosis.

The mechanism of action of ANG-(1–7), an active peptide fragment of the RAAS, is currently controversial. It has been reported to act as an angiotensin receptor antagonist and an ACE inhibitor, as well as altering prostaglandins and the bradykinin-nitric oxide system. These mechanisms have been exhaustively reviewed by Santos et al. (48) and others. The mechanisms may involve the reported mas receptor (59) or direct interaction with other angiotensin receptors (48).

There are several mechanisms by which ANG-(1–7) may decrease collagen deposition in models of hypertension. First, ANG-(1–7) could reduce blood pressure, which would decrease hemodynamic-dependent profibrotic signaling. Our results would not support this mechanism, because changes in blood pressures and pressor responses to acute ANG II were not observed by indirect or direct methods during chronic ANG-(1–7) treatment (Figs. 1 and 2). Second, ANG-(1–7) could directly inhibit the secretion of collagen or the activation of the fibroblasts or their differentiation into myofibroblasts. Third, ANG-(1–7) may increase collagen degradation by activating matrix metalloproteinases or by inhibiting tissue inhibitors of matrix metalloproteinases. Finally, ANG-(1–7) may inhibit the actions of various profibrotic factors such as norepinephrine, angiotensin II, TGF-beta, and/or endothelin-1, as ANG-(1–7) infusion has been reported to result in a reduction of cardiac ANG II levels (34). Future studies will be aimed at dissecting the possible mechanisms by which ANG-(1–7) reduces cardiac fibrosis in hypertension and to determine if this anti-fibrotic action also occurs in non-hypertensive fibrotic conditions.

This study also supports the idea that ANG-(1–7) has direct physiological actions, rather than simply being the result of metabolized ANG II. Our in vivo results are supported by a recent in vitro study (21). In this study, the authors examined angiotensin fragment binding in cultured adult rat cardiac fibroblasts, and showed that ANG-(1–7) binds to two separate sites that are unaffected by the AT1 receptor antagonist valsartan and the AT2 receptor antagonist PD-123, 319. Importantly, these authors showed that within the concentration ranges studied for binding, ANG-(1–7) inhibited collagen formation as measured by [3H]proline incorporation, and also decreased mRNA expression of various growth factors including TGF-beta1, endothelin-1, and leukemia inhibitory factor. Pretreatment of the cardiac fibroblasts with ANG-(1–7) inhibited ANG II-induced collagen protein. Together, the current in vivo study and the in vitro study by Iwata et al. (21) strongly support the hypothesis that ANG-(1–7) actively regulates cardiac fibrosis. These findings further indicate the significant role that ANG-(1–7) plays in the heart.

Our results parallel those of Loot et al. (31), who demonstrated cardioprotective effects of ANG-(1–7). In the current study, we utilized one-fourth of the dose of ANG-(1–7) that these authors employed. We did not determine the plasma or cardiac levels of ANG-(1–7) in the current study. It is conceivable that utilization of higher concentrations of ANG-(1–7) may result in greater cardioprotection, and it may also uncover effects on hypertrophy.

The results of the current study fit well with the findings of our recent study (20), in which systemic overexpression of ACE2 [the most important enzyme involved in ANG-(1–7) production] in angiotensin-infused hypertensive rats resulted in blood pressure-independent decreases in cardiac fibrosis. This study supports the concept that ACE2 mediates many (or most) of its protective effects through the production of ANG-(1–7). Myocardial infarction increases ACE2 expression in rats and humans (12). Averill et al. (4) also reported that ANG-(1–7) immunoreactivity was significantly increased in the ventricular tissue surrounding an area of myocardial infarction and absent in the remodeled area of infarction. Thus there is evidence suggesting that the ACE2 enzyme and the formation of ANG-(1–7) play significant roles in modifying cardiac remodeling.

Recently, Keidar et al. (25) demonstrated that the mineralocorticoid aldosterone significantly increased cardiac ACE and decreased ACE2 mRNA and activity levels in both humans and mice, whereas aldosterone antagonists produced the opposite responses. These data would suggest that ACE2 levels and the subsequent generation of ANG-(1–7) may be the mechanism by which mineralocorticoid receptor blockers improve cardiac function in myocardial infarct patients (40).

Several investigators (1, 33, 52) have demonstrated that chronic infusion of ANG II results in the development of hypertension, cardiac hypertrophy, and fibrosis. Functional ANG II receptors have been documented in cardiac fibroblasts (13), and ANG II-stimulated expression and secretion of collagen is completely abolished by AT1 and not AT2 receptor antagonism in vivo and in vitro (29, 30). Because ANG-(1–7) is significantly elevated with the use of AT1 antagonists (17), it is possible that some of the anti-fibrotic effects attributed to AT1 antagonism are mediated via actions of ANG-(1–7). In a preliminary study using a chronic ANG II-infusion model of hypertension, we observed a similar prevention of fibrosis (unpublished data) as was seen in the DOCA-salt model in the current paper, which further supports an anti-fibrotic effect of ANG-(1–7).

The development of cardiac fibrosis is a major complication of hypertensive cardiac disease. The increased deposition of basement membrane collagen is a hallmark of the remodeling process. This remodeling can predispose a patient to increased risk of adverse cardiac events, and therefore any reduction or reversal of cardiac fibrosis would facilitate the management of hypertensive heart disease. Our results suggest that ANG-(1–7) may be a beneficial component of the RAAS that provides this cardioprotection during hypertension, and any maneuver that would increase cardiac levels of ACE2 and subsequently ANG-(1–7) may be used as an effective therapeutic intervention in hypertensive heart disease patients.


   GRANTS
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
REFERENCES
 
J. L. Grobe was supported by an American Heart Association Pre-Doctoral Fellowship, and A. P. Mecca was supported by an Endocrine Society undergraduate summer research fellowship.


   FOOTNOTES
 

Address for reprint requests and other correspondence: M. J. Katovich, Dept. of Pharmacodynamics, College of Pharmacy, P. O. Box 100487, Univ. of Florida, Gainesville, FL 32610 (e-mail: katovich{at}cop.ufl.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.


   REFERENCES
TOP
 ABSTRACT
 MATERIALS AND METHODS
 RESULTS
 DISCUSSION
 GRANTS
 REFERENCES
 

  1. Abraham G and Simon G. Autopotentiation of pressor responses by subpressor angiotensin II in rats. Am J Hypertens 7: 269–275, 1994.[ISI][Medline]
  2. Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, and Laragh JH. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 324: 1098–1104, 1991.[Abstract]
  3. Anderson S, Rennke HG, and Brenner BM. Advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77: 1993–2000, 1986.[ISI][Medline]
  4. Averill DB, Ishiyama Y, Chappell MC, and Ferrario CM. Cardiac angiotensin-(1–7) in ischemic cardiomyopathy. Circulation 108: 2141–2146, 2003.[Abstract/Free Full Text]
  5. Bayorh MA, Eatman D, Walton M, Socci RR, Thierry-Palmer M, and Emmett N. A-779 attenuates angiotensin-(1–7) depressor response in salt-induced hypertensive rats. Peptides 23: 57–64, 2002.[CrossRef][ISI][Medline]
  6. Benetos A, Lacolley P, and Safar ME. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 17: 1152–1156, 1997.[Abstract/Free Full Text]
  7. Benter IF, Diz DI, and Ferrario CM. Pressor and reflex sensitivity is altered in spontaneously hypertensive rats treated with angiotensin-(1–7). Hypertension 26: 1138–1144, 1995.[Abstract/Free Full Text]
  8. Brilla CG, Janicki JS, and Weber KT. Impaired diastolic function and coronary reserve in genetic hypertension. Role of interstitial fibrosis and medial thickening of intramyocardial coronary arteries. Circ Res 69: 107–115, 1991.[Abstract/Free Full Text]
  9. Brilla CG and Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 120: 893–901, 1992.[ISI][Medline]
  10. Brosnihan KB, Li P, and Ferrario CM. Angiotensin-(1–7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 27: 523–528, 1996.[Abstract/Free Full Text]
  11. Brunner HR, Laragh JH, Baer L, Newton MA, Goodwin FT, Krakoff LR, Bard RH, and Buhler FR. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 286: 441–449, 1972.[ISI][Medline]
  12. Burrell LM, Risvanis J, Kubota E, Dean RG, MacDonald PS, Lu S, Tikellis C, Grant SL, Lew RA, Smith AI, Cooper ME, and Johnston CI. Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J 26: 369–375, 2005.[Abstract/Free Full Text]
  13. Crabos M, Roth M, Hahn AW, and Erne P. Characterization of angiotensin II receptors in cultured adult rat cardiac fibroblasts. Coupling to signaling systems and gene expression. J Clin Invest 93: 2372–2378, 1994.[ISI][Medline]
  14. Davie AP and McMurray JJ. Effect of angiotensin-(1–7) and bradykinin in patients with heart failure treated with an ACE inhibitor. Hypertension 34: 457–460, 1999.[Abstract/Free Full Text]
  15. Dobrzynski E, Wang C, Chao J, and Chao L. Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling, and renal injury in deoxycorticosterone acetate-salt hypertensive rats. Hypertension 36: 995–1001, 2000.[Abstract/Free Full Text]
  16. Eatman D, Wang M, Socci RR, Thierry-Palmer M, Emmett N, and Bayorh MA. Gender differences in the attenuation of salt-induced hypertension by angiotensin (1–7). Peptides 22: 927–933, 2001.[CrossRef][ISI][Medline]
  17. Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, and Gallagher PE. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 111: 2605–2610, 2005.[Abstract/Free Full Text]
  18. Ferreira AJ, Santos RA, and Almeida AP. Angiotensin-(1–7) improves the post-ischemic function in isolated perfused rat hearts. Braz J Med Biol Res 35: 1083–1090, 2002.[ISI][Medline]
  19. Funder J. Mineralocorticoids and cardiac fibrosis: the decade in review. Clin Exp Pharmacol Physiol 28: 1002–1006, 2001.[CrossRef][ISI][Medline]
  20. Huentelman MJ, Grobe JL, Vazquez J, Stewart JM, Mecca AP, Katovich MJ, Ferrario CM, and Raizada MK. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2. Exp Physiol 90: 783–790, 2005.[Abstract/Free Full Text]
  21. Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, and Greenberg BH. Angiotensin-(1–7) binds to specific receptors on cardiac fibroblasts to initiate anti-fibrotic and anti-trophic effects. Am J Physiol Heart Circ Physiol 289: H2356–H2363, 2005.[Abstract/Free Full Text]
  22. Iyer SN, Chappell MC, Averill DB, Diz DI, and Ferrario CM. Vasodepressor actions of angiotensin-(1–7) unmasked during combined treatment with lisinopril and losartan. Hypertension 31: 699–705, 1998.[Abstract/Free Full Text]
  23. Jalil JE, Janicki JS, Pick R, and Weber KT. Coronary vascular remodeling and myocardial fibrosis in the rat with renovascular hypertension. Response to captopril. Am J Hypertens 4: 51–55, 1991.[ISI][Medline]
  24. Katovich MJ, Reaves PY, Francis SC, Pachori AS, Wang HW, and Raizada MK. Gene therapy attenuates the elevated blood pressure and glucose intolerance in an insulin-resistant model of hypertension. J Hypertens 19: 1553–1558, 2001.[CrossRef][ISI][Medline]
  25. Keidar S, Gamliel-Lazarovich A, Kaplan M, Pavlotzky E, Hamoud S, Hayek T, Karry R, and Abassi Z. Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ Res 97: 946–953, 2005.[Abstract/Free Full Text]
  26. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F, and Iwao H. Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 24: 195–204, 1994.[Abstract/Free Full Text]
  27. Lekgabe ED, Kiriazis H, Zhao C, Xu Q, Moore XL, Su Y, Bathgate RA, Du XJ, and Samuel CS. Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 46: 412–418, 2005.[Abstract/Free Full Text]
  28. Le Tran Y and Forster C. Angiotensin-(1–7) and the rat aorta: modulation by the endothelium. J Cardiovasc Pharmacol 30: 676–682, 1997.[CrossRef][ISI][Medline]
  29. Lijnen P and Petrov V. Antagonism of the renin-angiotensin-aldosterone system and collagen metabolism in cardiac fibroblasts. Methods Find Exp Clin Pharmacol 21: 215–227, 1999.[CrossRef][ISI][Medline]
  30. Lijnen PJ, Petrov VV, and Fagard RH. Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptors. J Renin Angiotensin Aldosterone Syst 2: 117–122, 2001.[ISI][Medline]
  31. Loot AE, Roks AJ, Henning RH, Tio RA, Suurmeijer AJ, Boomsma F, and van Gilst WH. Angiotensin-(1–7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 105: 1548–1550, 2002.[Abstract/Free Full Text]
  32. Lu D, Raizada MK, Iyer S, Reaves P, Yang H, and Katovich MJ. Losartan versus gene therapy: chronic control of high blood pressure in spontaneously hypertensive rats. Hypertension 30: 363–370, 1997.[Abstract/Free Full Text]
  33. Melargno M and Fink G. Inhibition of the slow pressor effect of angiotensin II contributes to the antihypertensive effect of angiotensin converting enzyme inhibitors in renovascular hypertension. J Pharmacol Exp Ther 278: 297–303, 1996.[Abstract/Free Full Text]
  34. Mendes AC, Ferreira AJ, Pinheiro SV, and Santos RA. Chronic infusion of angiotensin-(1–7) reduces heart angiotensin II levels in rats. Regul Pept 125: 29–34, 2005.[CrossRef][ISI][Medline]
  35. Nehme JA, Lacolley P, Labat C, Challande P, Robidel E, Perret C, Leenhardt A, Safar ME, Delcayre C, and Milliez P. Spironolactone improves carotid artery fibrosis and distensibility in rat post-ischaemic heart failure. J Mol Cell Cardiol 39: 511–519, 2005.[CrossRef][ISI][Medline]
  36. Neves LA, Averill DB, Ferrario CM, Aschner JL, and Brosnihan KB. Vascular responses to angiotensin-(1–7) during the estrous cycle. Endocrine 24: 161–165, 2004.[CrossRef][ISI][Medline]
  37. Nishikawa K. Angiotensin AT1 receptor antagonism and protection against cardiovascular end-organ damage. J Hum Hypertens 12: 301–309, 1998.[CrossRef][ISI][Medline]
  38. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ, Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, and Flaker GC. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial The SAVE Investigators. N Engl J Med 327: 669–677, 1992.[Abstract]
  39. Pinto YM, de Smet BG, van Gilst WH, Scholtens E, Monnink S, de Graeff PA, and Wesseling H. Selective and time related activation of the cardiac renin-angiotensin system after experimental heart failure: relation to ventricular function and morphology. Cardiovasc Res 27: 1933–1938, 1993.[Abstract/Free Full Text]
  40. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M, and Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348: 1309–1321, 2003.[Abstract/Free Full Text]
  41. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, and Chang PI. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349: 747–752, 1997.[CrossRef][ISI][Medline]
  42. Rasband WS ImageJ [Online]. U.S. National Institutes of Health, Bethesda, MD. http://rsb.info.nih.gov/ij [1997–2005].
  43. Ren Y, Garvin JL, and Carretero OA. Vasodilator action of angiotensin-(1–7) on isolated rabbit afferent arterioles. Hypertension 39: 799–802, 2002.[Abstract/Free Full Text]
  44. Rocha R and Stier CT. Pathophysiological effects of aldosterone in cardiovascular tissues. Trends Endocrinol Metab 12: 308–314, 2001.[CrossRef][ISI][Medline]
  45. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, and Adler GK. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 141: 3871–3878, 2000.[Abstract/Free Full Text]
  46. Sampaio WO, Nascimento AA, and Santos RA. Systemic and regional hemodynamic effects of angiotensin-(1–7) in rats. Am J Physiol Heart Circ Physiol 284: H1985–H1994, 2003.[Abstract/Free Full Text]
  47. Santos RA, Brum JM, Brosnihan KB, and Ferrario CM. The renin-angiotensin system during acute myocardial ischemia in dogs. Hypertension 15: I121–I127, 1990.[ISI][Medline]
  48. Santos RA, Campagnole-Santos MJ, and Andrade SP Angiotensin-(1–7): an update. Regul Pept 91: 45–62, 2000.[CrossRef][ISI][Medline]
  49. Santos RA, Ferreira AJ, Nadu AP, Braga AN, de Almeida AP, Campagnole-Santos MJ, Baltatu O, Iliescu R, Reudelhuber TL, and Bader M. Expression of an angiotensin-(1–7)-producing fusion protein produces cardioprotective effects in rats. Physiol Genomics 17: 292–299, 2004.[Abstract/Free Full Text]
  50. Sasaki S, Higashi Y, Nakagawa K, Matsuura H, Kajiyama G, and Oshima T. Effects of angiotensin-(1–7) on forearm circulation in normotensive subjects and patients with essential hypertension. Hypertension 38: 90–94, 2001.[Abstract/Free Full Text]
  51. Schunkert H, Tang SS, Litwin SE, Diamant D, Riegger G, Dzau VJ, and Ingelfinger JR. Regulation of intrarenal and circulating renin-angiotensin systems in severe heart failure in the rat. Cardiovasc Res 27: 731–735, 1993.[Abstract/Free Full Text]
  52. Simon G, Abranham G, and Cserep G. Pressor and subpressor angiotensin II administration. Two experimental models of hypertension. Am J Hypertens 8: 645–650, 1995.[CrossRef][ISI][Medline]
  53. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327: 685–691, 1992.[Abstract]
  54. Stegbauer J, Vonend O, Oberhauser V, and Rump LC. Effects of angiotensin-(1–7) and other bioactive components of the renin-angiotensin system on vascular resistance and noradrenaline release in rat kidney. J Hypertens 21: 1391–1399, 2003.[CrossRef][ISI][Medline]
  55. Stier CT Jr, Chander P, Gutstein WH, Levine S, and Itskovitz HD. Therapeutic benefit of captopril in salt-loaded stroke-prone spontaneously hypertensive rats is independent of hypotensive effect. Am J Hypertens 4: 680–687, 1991.[ISI][Medline]
  56. Stier CT Jr, Adler LA, Levine S, and Chander PN. Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats. J Hypertens Suppl 11: S37–S42, 1993.[CrossRef][Medline]
  57. Stier CT, Jr, Benter IF, Ahmad S, Zuo HL, Selig N, Roethel S, Levine S, and Itskovitz HD. Enalapril prevents stroke and kidney dysfunction in salt-loaded stroke-prone spontaneously hypertensive rats. Hypertension 13: 115–121, 1998.
  58. Takeda Y, Yoneda T, Demura M, Usukura M, and Mabuchi H. Calcineurin inhibition attenuates mineralocorticoid-induced cardiac hypertrophy. Circulation 105: 677–679, 2002.[Abstract/Free Full Text]
  59. Tallant EA, Ferrario CM, and Gallagher PE. Angiotensin-(1–7) inhibits growth of cardiac myocytes through activation of the mas receptor. Am J Physiol Heart Circ Physiol 289: H1560–H1566, 2005.[Abstract/Free Full Text]
  60. Thurmann PA, Kenedi P, Schmidt A, Harder S, and Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 98: 2037–2042, 1998.[Abstract/Free Full Text]
  61. Weber KT. Fibrosis and hypertensive heart disease. Curr Opin Cardiol 15: 264–272, 2000.[CrossRef][ISI][Medline]
  62. Weber KT and Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 83: 1849–1865, 1991.[Abstract/Free Full Text]
  63. Weber KT. Hormones and fibrosis: a case for lost, reciprocal regulation. News Physiol Sci 9: 123–128, 1994.[Abstract/Free Full Text]
  64. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 345: 1689–1697, 2001.[Free Full Text]
  65. Wilsdorf T, Gainer JV, Murphey LJ, Vaughan DE, and Brown NJ. Angiotensin-(1–7) does not affect vasodilator or TPA responses to bradykinin in human forearm. Hypertension 37: 1136–1140, 2001.[Abstract/Free Full Text]
  66. Young M and Funder JW. Aldosterone and the heart. Trends Endocrinol Metab 11: 224–226, 2000.[CrossRef][ISI][Medline]
  67. Young M and Funder J. Mineralocorticoid action and sodium-hydrogen exchange: studies in experimental cardiac fibrosis. Endocrinology 144: 3848–3851, 2003.[Abstract/Free Full Text]
  68. Young M, Fullerton M, Dilley R, and Funder J. Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest 93: 2578–2583, 1994.[ISI][Medline]
  69. Young M, Head G, and Funder J. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol Endocrinol Metab 269: E657–E662, 1995.[Abstract/Free Full Text]
  70. Zhu Z, Zhong J, Zhu S, Liu D, Van Der Giet M, Tepel Zhu Z M, Zhong J, Zhu S, Liu D, Van Der Giet M, and Tepel M. Angiotensin-(1–7) inhibits angiotensin II-induced signal transduction. J Cardiovasc Pharmacol 40: 693–700, 2002.[CrossRef][ISI][Medline]



This article has been cited by other articles:


Home page
 Exp PhysiolHome page
J. F. Giani, M. M. Gironacci, M. C. Munoz, D. Turyn, and F. P. Dominici
Angiotensin-(1-7) has a dual role on growth-promoting signalling pathways in rat heart in vivo by stimulating STAT3 and STAT5a/b phosphorylation and inhibiting angiotensin II-stimulated ERK1/2 and Rho kinase activity
Exp Physiol, May 1, 2008; 93(5): 570 - 578.
[Abstract] [Full Text] [PDF]

Home page
 Exp PhysiolHome page
A. G. Filho, A. J. Ferreira, S. H. S. Santos, S. R. S. Neves, E. R. Silva Camargos, L. K. Becker, H. A. Belchior, M. F. Dias-Peixoto, S. V. B. Pinheiro, and R. A. S. Santos
Selective increase of angiotensin(1-7) and its receptor in hearts of spontaneously hypertensive rats subjected to physical training
Exp Physiol, May 1, 2008; 93(5): 589 - 598.
[Abstract] [Full Text] [PDF]

Home page
 Exp PhysiolHome page
L. Burchill, E. Velkoska, R. G. Dean, R. A. Lew, A. I. Smith, V. Levidiotis, and L. M. Burrell
Acute kidney injury in the rat causes cardiac remodelling and increases angiotensin-converting enzyme 2 expression
Exp Physiol, May 1, 2008; 93(5): 622 - 630.
[Abstract] [Full Text] [PDF]

Home page
 Exp PhysiolHome page
C.-H. Pan, C.-H. Wen, and C.-S. Lin
Interplay of angiotensin II and angiotensin(1-7) in the regulation of matrix metalloproteinases of human cardiocytes
Exp Physiol, May 1, 2008; 93(5): 599 - 612.
[Abstract] [Full Text] [PDF]

Home page
 Exp PhysiolHome page
P. J. Garabelli, J. G. Modrall, J. M. Penninger, C. M. Ferrario, and M. C. Chappell
Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart
Exp Physiol, May 1, 2008; 93(5): 613 - 621.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
J. A. Hernandez Prada, A. J. Ferreira, M. J. Katovich, V. Shenoy, Y. Qi, R. A.S. Santos, R. K. Castellano, A. J. Lampkins, V. Gubala, D. A. Ostrov, et al.
Structure-Based Identification of Small-Molecule Angiotensin-Converting Enzyme 2 Activators as Novel Antihypertensive Agents
Hypertension, May 1, 2008; 51(5): 1312 - 1317.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
P. Xu, A. C. Costa-Goncalves, M. Todiras, L. A. Rabelo, W. O. Sampaio, M. M. Moura, S. Sousa Santos, F. C. Luft, M. Bader, V. Gross, et al.
Endothelial Dysfunction and Elevated Blood Pressure in Mas Gene-Deleted Mice
Hypertension, February 1, 2008; 51(2): 574 - 580.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
M. C. Chappell
Emerging Evidence for a Functional Angiotensin-Converting Enzyme 2-Angiotensin-(1-7)-Mas Receptor Axis: More Than Regulation of Blood Pressure?
Hypertension, October 1, 2007; 50(4): 596 - 599.
[Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
A. J. Trask, D. B. Averill, D. Ganten, M. C. Chappell, and C. M. Ferrario
Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats
Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H3019 - H3024.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. GenomicsHome page
C. Diez-Freire, J. Vazquez, M. F. Correa de Adjounian, M. F. R. Ferrari, L. Yuan, X. Silver, R. Torres, and M. K. Raizada
ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR
Physiol Genomics, January 12, 2007; 27(1): 12 - 19.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
290/6/H2417    most recent
01170.2005v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (18)
Right arrow